Eptinezumab for the prevention of chronic migraine: efficacy and safety through 24 weeks of treatment in the phase 3 PROMISE-2 (Prevention of migraine via intravenous ALD403 safety and efficacy–2) study - Silberstein, Stephen; Diamond, Merle; Hindiyeh, Nada A.; Biondi, David M.; Cady, Roger; Hirman, Joe; Allan, Brent; Pederson, Susan; Schaeffler, Barbara; Smith, Jeff (Journal of headache and pain, 2020)
Keywords: Adult; Antibodies, Monoclonal, Humanized; Calcitonin Gene-Related Peptide; Chronic migraine; Double-Blind Method; Efficacy; Eptinezumab; Humans; Internal Medicine; Medicine; Medicine & Public Health; Migraine Disorders - drug therapy; Migraine Disorders - prevention & control; Neurology; Pain Medicine; Research Article; Safety; Treatment Outcome; Chronic migraine; Efficacy; Safety; Eptinezumab